Cerebral Microbleeds and Treatment Effect of Intravenous Thrombolysis in Acute Stroke

Abstract

Background and ObjectivesCerebral microbleeds (CMBs) are common in acute ischemic stroke patients and are associated with increased risk of intracerebral hemorrhage (ICH) after intravenous thrombolysis. Whether CMBs modify the treatment effect of thrombolysis is unknown.MethodsWe performed a pre-specified analysis of the prospective randomized controlled multicenter WAKE-UP trial including patients with acute ischemic stroke with unknown time of symptom onset and DWI-FLAIR mismatch on MRI receiving alteplase or placebo. Patients were screened and enrolled between September 2012 and June 2017 (with final follow-up in September 2017). Patients were randomized to treatment with intravenous thrombolysis with alteplase at 0.9 mg / kg body weight or placebo. CMB status (presence, number, and distribution) was assessed after study completion by three raters blinded to clinical information following a standardized protocol. Outcome measures were excellent functional outcome at 90 days, defined by modified Rankin Scale score (mRS)≤1, and symptomatic intracerebral hemorrhage (ICH) according to NINDS trial criteria 22 to 36 hours after treatment.ResultsOf 503 patients enrolled in the WAKE-UP trial, 459 (91.3%; 288 [63%] men) were available for analysis; 98 (21.4%) had at least 1 CMB on baseline imaging; 45 (9.8%) had exactly 1 CMB, 37 (8.1%) had 2-4 CMBs, and 16 (3.5%) had ≥5 CMBs. Presence of CMBs was associated with a non-significant increased risk of symptomatic ICH (11.2% versus 4.2%; adjusted odds ratio 2.32 [95% CI 0.99-5.43]; P=.052), but had no effect on functional outcome at 90 days (mRS≤1: 45.8% versus 50.7%; adj. OR 0.99 [0.59-1.64]; P=.955). Patients receiving alteplase had better functional outcome (mRS≤1: 54.6% versus 44.6%, adj. OR 1.61 [1.07-2.43], P=.022) without evidence of heterogeneity in relation to CMB presence (P value of the interactive term .546). Results were similar for subpopulations with strictly lobar (presumed cerebral amyloid angiopathy-related) or non-strictly-lobar CMB distribution.DiscussionIn the randomized-controlled WAKE-UP trial, we saw no evidence of reduced treatment effect of alteplase in acute ischemic stroke patients with one or more CMBs. Additional studies are needed to determine the treatment effect of alteplase and its benefit-harm-ratio in patients with a larger number of CMBs.Trial registrationClinicalTrials.gov number, NCT01525290 (https://clinicaltrials.gov/ct2/show/NCT01525290); EudraCT number, 2011-005906-32 (https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005906-32/GB).Classification of EvidenceThis study provides Class II evidence that for patients with acute ischemic stroke with unknown time of onset and DWI-FLAIR mismatch who received IV alteplase, CMBs are not significantly associated with functional outcome at 90 days.

Influence of cerebral microbleeds on mechanical thrombectomy outcomes

“…The results of this study do not suggest absence of treatment effect of EVT in the high CMB population, and should not be used as evidence for excluding patients from a powerful treatment modality. A recent study using data from a randomized IV thrombolysis has shown no reduced treatment effect of alteplase in acute ischemic stroke patients with one or more CMBs 33 , while reaching inconclusive conclusions regarding larger numbers of CMBs. Similarly designed studies will be needed regarding EVT treatment effect.…”

A novel rat model for cerebral venous sinus thrombosis: verification of similarity to human disease via clinical analysis and experimental validation

“…Patients were followed up via telephone, and a total of 34 patients with valid information were included. Outcomes were assessed based on the mRS, with an mRS ≤ 1 defined as good recovery [ 17 ]. Mental status was assessed using the Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), and Hamilton Depression Scale (HAMD).…”

Predictive Factors for Early-Onset Seizures in Patients With Cerebral Venous Sinus Thrombosis

“…Seizures that occurred before admission were recorded based on witness descriptions. NIHSS and mRS scores at admission were recorded to assess stroke severity in patients with CVST ( 12 , 13 ). Laboratory data were available for each patient at admission as part of an emergency or routine admission checkup.…”